These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3141993)

  • 1. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
    Yen TT; Fuller RW; Broderick CL; Hemrick-Luecke SK; Perry KW
    Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):257-60. PubMed ID: 3141993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
    J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
    Griffin BW; McNatt LG; Chandler ML; York BM
    Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
    Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
    J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an aldose reductase inhibitor on altered sympathetic nerve responsiveness of isolated right atria in diabetic rats.
    Sato N; Hashimoto H; Takiguchi Y; Nakashima M
    Arzneimittelforschung; 1990 Jul; 40(7):763-6. PubMed ID: 2121149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ponalrestat on sorbitol levels in the lens of obese and diabetic mice.
    Vicario PP; Slater EE; Saperstein R
    Biochem Int; 1989 Sep; 19(3):553-61. PubMed ID: 2510726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix.
    Aida K; Tawata M; Shindo H; Onaya T; Sasaki H; Yamaguchi T; Chin M; Mitsuhashi H
    Planta Med; 1990 Jun; 56(3):254-8. PubMed ID: 2118267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of insulin on aldose reductase activity in the lens of rats with streptozotocin-induced diabetes].
    Nishigami T
    Nippon Ganka Gakkai Zasshi; 1990 Feb; 94(2):128-34. PubMed ID: 2114733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats.
    Suárez G; Rajaram R; Bhuyan KC; Oronsky AL; Goidl JA
    J Clin Invest; 1988 Aug; 82(2):624-7. PubMed ID: 3136193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of potent aldose reductase inhibitors having a hydantoin structure.
    Miwa I; Hirano M; Inagaki K; Belbeoc'h C; Okuda J
    Biochem Pharmacol; 1987 Sep; 36(17):2789-94. PubMed ID: 3115267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors.
    Tilton RG; Chang K; Pugliese G; Eades DM; Province MA; Sherman WR; Kilo C; Williamson JR
    Diabetes; 1989 Oct; 38(10):1258-70. PubMed ID: 2507378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y; Terashima H; Morimura T; Tsuboshima M
    Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an aldose reductase inhibitor, AL-1576, on the development of UV-B and X-ray cataract.
    Schmitt C; Schmidt J; Wegener A; Hockwin O
    Graefes Arch Clin Exp Ophthalmol; 1988; 226(5):455-60. PubMed ID: 3142804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats.
    Liu TP; Juang SW; Cheng JT; Tong YC
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):131-5. PubMed ID: 15936525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altering the course of cataracts in diabetic rats.
    Fukushi S; Merola LO; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1980 Mar; 19(3):313-5. PubMed ID: 6766909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of lens aldose reductase activity by nitric oxide.
    Srivastava S; Tammali R; Chandra D; Greer DA; Ramana KV; Bhatnagar A; Srivastava SK
    Exp Eye Res; 2005 Dec; 81(6):664-72. PubMed ID: 15967436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
    Kojima K; Matsubara H; Harada T; Mizuno K; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Jpn J Ophthalmol; 1985; 29(1):99-109. PubMed ID: 3159927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spiro hydantoin aldose reductase inhibitors.
    Sarges R; Schnur RC; Belletire JL; Peterson MJ
    J Med Chem; 1988 Jan; 31(1):230-43. PubMed ID: 3121857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.